- Home
- IONS vs DBX Comparison
IONS vs DBX Comparison
Compare IONS & DBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- DBX
- Stock Information
- Founded
- IONS 1989
- DBX 2007
- Country
- IONS United States
- DBX United States
- Employees
- IONS N/A
- DBX N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- DBX Computer Software: Prepackaged Software
- Sector
- IONS Health Care
- DBX Technology
- Exchange
- IONS Nasdaq
- DBX Nasdaq
- Market Cap
- IONS 6.8B
- DBX 7.7B
- IPO Year
- IONS 1991
- DBX 2018
- Fundamental
- Price
- IONS $61.23
- DBX $29.87
- Analyst Decision
- IONS Buy
- DBX Hold
- Analyst Count
- IONS 17
- DBX 5
- Target Price
- IONS $67.88
- DBX $30.50
- AVG Volume (30 Days)
- IONS 3.1M
- DBX 3.3M
- Earning Date
- IONS 07-30-2025
- DBX 08-07-2025
- Dividend Yield
- IONS N/A
- DBX N/A
- EPS Growth
- IONS N/A
- DBX N/A
- EPS
- IONS N/A
- DBX 1.57
- Revenue
- IONS $944,050,000.00
- DBX $2,532,800,000.00
- Revenue This Year
- IONS $24.30
- DBX N/A
- Revenue Next Year
- IONS $7.39
- DBX N/A
- P/E Ratio
- IONS N/A
- DBX $19.05
- Revenue Growth
- IONS 16.05
- DBX N/A
- 52 Week Low
- IONS $23.95
- DBX $22.72
- 52 Week High
- IONS $62.08
- DBX $33.33
- Technical
- Relative Strength Index (RSI)
- IONS 83.44
- DBX 66.55
- Support Level
- IONS $42.13
- DBX $28.27
- Resistance Level
- IONS $62.08
- DBX $29.21
- Average True Range (ATR)
- IONS 2.11
- DBX 0.56
- MACD
- IONS 2.09
- DBX 0.14
- Stochastic Oscillator
- IONS 95.83
- DBX 99.02
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.